Murine Plasmacytoma Cells Research Articles

Expression of nuclear lamins in mammalian somatic cells lacking cytoplasmic intermediate filament proteins.

Using immunofluorescence and immunoblotting techniques, we have examined the composition of the nuclear lamina in murine plasmacytoma cells, MPC-11, exposed to the phorbol ester TPA as well as in two cell lines devoid of cytoplasmic intermediate filament proteins, the human adrenal cortex carcinoma-derived cells SW-13 and the clone C6-M-D4 derived from the rat glial cell line C6. Our results show that the inhibition of proliferation and the induction of vimentin synthesis observed in TPA-treated MPC-11 populations are not paralleled by changes in the lamin complement of these cells, which contain lamin B but lack lamins A and C. Furthermore, the analysis performed on SW-13 and C6-M-D4 cell lines clearly demonstrates that mammalian somatic cells display considerable variations in lamin expression and indicates that lamin B may be the only lamin species constitutively expressed in mammalian cells.

Purification and characterization of UV endonucleases I and II from murine plasmacytoma cells

Three endonucleases from murine plasmacytoma cells that specifically nick DNA which was heavily irradiated with ultraviolet (UV) light were resolved by Sephacryl S-200 column chromatography. Two of these, UV endonucleases I and II, were purified extensively. UV endonuclease I appears to be a monomeric protein with a molecular mass of 43 kDa; UV endonuclease II has an S value of 2.9 S, with a corresponding molecular mass estimated at 28 kDa. Both enzymes act as a class I AP endonuclease, cleaving phosphodiester bonds via a beta-elimination mechanism, so as to form an unsaturated deoxyribose at the 3' terminus. Both have thymine glycol DNA glycosylase activity and their substrate specificities generally appear to be overlapping but not identical. UV endonuclease I acts on both supercoiled and relaxed DNAs, whereas II acts only on supercoiled DNA. Both enzymes are active in EDTA, but have different optima for salt, pH, and Triton X-100. Each enzyme is also present in cultured diploid human fibroblasts.

Purified mu EBP-E binds to immunoglobulin enhancers and promoters.

We describe the purification to apparent homogeneity of the murine immunoglobulin heavy-chain (IgH) enhancer-binding protein mu EBP-E from murine plasmacytoma cells by ion exchange and affinity chromatography. Glycerol gradient sedimentation, UV cross-linking, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis confirm that mu EBP-E is a 45-kilodalton molecular mass protein. Orthophenanthroline-copper chemical nuclease footprinting with purified protein has identified high-affinity binding sites for mu EBP-E within the IgH enhancer at the previously identified site E and at sites within IgH promoters and in the kappa light-chain enhancer. Equilibrium binding studies indicate that the dissociation constants for mu EBP-E binding to site E within the enhancer and to a binding site within the V1 heavy-chain promoter are quite low, about 2 x 10(-11) M. Comparison of four mu EBP-E recognition sequences detects only limited sequence similarity among binding sites.

Purified mu EBP-E binds to immunoglobulin enhancers and promoters.

We describe the purification to apparent homogeneity of the murine immunoglobulin heavy-chain (IgH) enhancer-binding protein mu EBP-E from murine plasmacytoma cells by ion exchange and affinity chromatography. Glycerol gradient sedimentation, UV cross-linking, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis confirm that mu EBP-E is a 45-kilodalton molecular mass protein. Orthophenanthroline-copper chemical nuclease footprinting with purified protein has identified high-affinity binding sites for mu EBP-E within the IgH enhancer at the previously identified site E and at sites within IgH promoters and in the kappa light-chain enhancer. Equilibrium binding studies indicate that the dissociation constants for mu EBP-E binding to site E within the enhancer and to a binding site within the V1 heavy-chain promoter are quite low, about 2 x 10(-11) M. Comparison of four mu EBP-E recognition sequences detects only limited sequence similarity among binding sites.

Identification of a set of calcium-binding proteins in reticuloplasm, the luminal content of the endoplasmic reticulum.

A procedure was developed for the isolation of reticuloplasm, the luminal material of the endoplasmic reticulum (ER). A reticuloplasm-rich extract was prepared from a murine plasmacytoma cell line that contains large amounts of ER, by first extracting the cytoplasmic contents using hypotonic lysis to yield ER-rich 'shells' followed by mechanical lysis to release the ER contents. The extract contains five major proteins with apparent molecular weights of 100, 75, 60, 58 and 55 (X 10(3] Mr by SDS-polyacrylamide gel electrophoresis. The 100, 75 and 58 (X 10(3] Mr species were identified as the known ER proteins endoplasmin, BiP and PD1, respectively. The ER association of the 60 and 55 (X 10(3] Mr proteins was confirmed by confocal fluorescence microscopy with affinity-purified antibodies. Equilibrium dialysis with isolated reticuloplasm gave a calcium-binding capacity of 300 nmoles calcium per mg protein with half-maximal binding at 3 mM-Ca2+. Purified endoplasmin bound 280 nmoles calcium per mg protein at a calcium concentration of 5 mM-Ca2+. A calcium overlay test revealed that, in addition to endoplasmin, reticuloplasm contained at least three other calcium-binding proteins: i.e. BiP, PDI and the 55 X 10(3) Mr protein, respectively, with endoplasmin and the 55 X 10(3) Mr protein (CRP55) accounting for the major proportion of the calcium-binding activity. Treatment of cells with calcium ionophore led to the specific over-expression of the major calcium-binding reticuloplasmins endoplasmin, BiP and CRP55. These studies show that the lumen of the ER contains a family of proteins with the capacity to bind significant amounts of calcium in the millimolar range and thereby to confer upon the ER the ability to perform a calcium storage function analogous to that of the sarcoplasmic reticulum in muscle cells.

De novo and maintenance DNA methylation by a mouse plasmacytoma cell DNA methyltransferase.

A DNA methyltransferase of Mr = 140,000 that is active on both unmethylated and hemimethylated DNA substrates has been purified from the murine plasma-cytoma cell line MPC 11. The maximal rate of methylation was obtained with maintenance methylation of hemimethylated Micrococcus luteus or M13 DNAs. At low enzyme concentrations, the highest rate of de novo methylation occurred with single-stranded DNA or relatively short duplex DNA containing single-stranded regions. Strong substrate inhibition was observed with hemimethylated but not unmethylated DNA substrates. Fully methylated single-stranded M13 phage DNA inhibited neither the de novo nor the maintenance reactions, but unmethylated single-stranded M13 DNA strongly inhibited the maintenance reaction. The kinetics observed with hemimethylated and single-stranded substrates could be explained if the enzyme were to bind irreversibly to a DNA molecule and to aggregate if present in molar excess. Such aggregates would be required for activity upon hemimethylated but not single-stranded DNA. For de novo methylation of duplex DNA, single-stranded regions or large amounts of methyltransferase appear to be required. The relative substrate preference for the enzyme is hemimethylated DNA greater than fully or partially single-stranded DNA greater than fully duplex DNA.

A phenotypically dominant regulatory mechanism suppresses major histocompatibility complex class II gene expression in a murine plasmacytoma.

The expression of major histocompatibility complex (MHC) class II antigens is down-regulated when B cells differentiate into plasma cells. We have studied the mechanism of down-regulation of MHC class II expression in a BALB/c strain-derived murine plasmacytoma cell line, NS1. NS1 cells express MHC class I antigens but not MHC class II antigens. We tested 20 uncloned hybrid cell lines obtained from the fusion of NS1 cells with MHC class II-expressing splenic B cells prepared from CBA, SJL or BALB/c mice. All the hybrid cell lines expressed MHC class I antigens of either or both parental haplotypes but did not express MHC class II. One NS1 X splenic B cell hybrid clone, K3, was used to further validate these results; K3 cells expressed MHC class I but not MHC class II antigens. K3 was fused to the MHC class II-expressing B lymphoma A20, and the seven resulting hybrid cell lines were again found to express MHC class I but not MHC class II antigens. Since NS1 is a subclone of the P3-X63Ag8 murine plasmacytoma, we also tested one P3-X63Ag8 x splenic B cell hybrid, Sp2/0, and two Sp2/0 x splenic B cell hybrids. All were found to express the appropriate MHC class I antigens but did not express MHC class II. Thus, our results suggest that the NS1 plasmacytoma suppresses MHC class II expression by a phenotypically dominant regulatory mechanism. We found that NS1 cells express correctly sized mRNA for the MHC class II genes A alpha, E alpha and the invariant chain. The co-expression of MHC class I protein and I-A and I-E region gene transcripts provides strong evidence that the MHC gene cluster is structurally intact, and that lack of class II expression is due to a genetic regulatory mechanism. The amounts of class II mRNA expressed by NS1 cells were at least equivalent to those found in splenic lymphocytes. Therefore, this regulation must operate post-transcriptionally.

Encapsulation of viable cells within polyacrylate membranes

A new, semipermeable hydrogel membrane for encapsulating viable cells has been developed. The encapsulation was performed by consecutively introducing droplets of a suspension of hybridoma cells in a solution of a polyanionic acrylic copolymer into aqueous solutions of three polycationic polymers. As a result of interpolymeric ionic interactions and some chemical reactions, a polyelectrolyte complex membrane was formed at the interface between each droplet and the polycationic polymeric solutions. The hybridoma cells, used as a model system, were derived by fusing spleen cells from immunized BALB/c mice with the NS-1 murine plasmacytoma cell line. The cells divided and gradually filled the microcapsules over a period of 8 days. Prior to encapsulation of the hybridoma cells, the polyanions were tested for toxicity and inhibition of cell growth. A direct relationship was observed between hybridoma cell viability in the acrylic polyanion/RPMI-1640/10% (w/v) fetal calf serum (FCS) solutions and the kinematic viscosities of the solutions of the polyanions. Antihuman IgM was produced by the encapsulated hybridoma cells and immunoassay showed that the antibody concentration was 3 mug/ml of the total culture medium.

Oligosaccharide processing at individual glycosylation sites on MOPC 104E immunoglobulin M. Differences in alpha 1,2-linked mannose processing.

Processing of the asparagine-linked oligosaccharides at the known glycosylation sites on the mu-chain of IgM secreted by MOPC 104E murine plasmacytoma cells was investigated. Oligosaccharides present on intracellular mu-chain precursors were of the high mannose type, remaining susceptible to endo-beta-N-acetylglucosaminidase H. However, only 26% of the radioactivity was released from [3H]mannose-labeled secreted IgM glycopeptides, consistent with the presence of high mannose-type and complex-type oligosaccharides on the mature mu-chain. [3H]Mannose-labeled cyanogen bromide glycopeptides derived from mu-chains of secreted IgM were isolated and analyzed to identify the glycopeptide containing the high mannose-type oligosaccharide from those containing complex-type structures. [3H]Mannose-labeled intracellular mu-chain cyanogen bromide glycopeptides corresponding to those from secreted IgM were isolated also, and the time courses of oligosaccharide processing at the individual glycosylation sites were determined. The major oligosaccharides on all intracellular mu-chain glycopeptides after 20 min of pulse labeling with [3H]mannose were identified as Man8GlcNAc2, Man9GlcNAc2, and Glc1Man9GlcNAc2. Processing of the oligosaccharide destined to become the high mannose-type structure on the mature protein was rapid. After 30 min of chase incubation the predominant structures of this oligosaccharide were Man5GlcNAc2 and Man6GlcNAc2 which were also identified on the high mannose-type oligosaccharide of the secreted mu-chain. In contrast, processing of oligosaccharides destined to become complex type was considerably slower. Even after 180 min of chase incubation, Man7GlcNAc2 and Man8GlcNAc2 were the predominant structures at some of these glycosylation sites. The isomeric structures of Man8GlcNAc2 obtained from all of the glycosylation sites were identical. Thus, the different rates of processing were not the result of a different sequence of alpha 1,2-mannose removal.

Sympathectomy inhibits growth of a murine plasmacytoma tumor

The effects of 6-hydroxydopamine (6-OHDA), N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) and anti-nerve growth factor (anti-NGF) on the development and growth of a tumor of non-neuronal origin were studied in mice. Murine LPC-1 plasmacytoma cells were grown either subcutaneously (s.c.) as solid tumors in the hindleg or intraperitoneally (i.p.) in ascitic form. Growth of s.c. tumors was monitored by caliper measurements of the hindleg at the site of tumor cell inoculation; growth of ascitic tumors was followed by electrophoretic determination in plasma of the tumor associated protein IgG 2aκ, M component. Adult mice were treated with 6-OHDA or DSP-4 six hours prior to tumor cell implantation; newborn mice were treated with anti-NGF and tumor cells were given 9 weeks later. Both chemical- and immunosympathectomy significantly altered the growth pattern of solid and ascitic tumors ( P < 0.0001). The effect of sympathectomy on the growth of solid tumors was most pronounced during the early phase of tumor growth. The data document that the effect of each drug treatment on tumor growth was not due not due to direct cytotoxic actions of the agents employed on tumor cells but the result of impairment of sympathetic functions. The findings of this study suggest a role of the sympathetic nervous system in tumor growth.

Processing of MOPC 315 immunoglobulin A oligosaccharides: evidence for endoplasmic reticulum and trans Golgi alpha 1,2-mannosidase activity.

The processing of asparagine-linked oligosaccharides on the alpha-chains of an immunoglobulin A (IgA) has been investigated using MOPC 315 murine plasmacytoma cells. These cells secrete IgA containing complex-type oligosaccharides that were not sensitive to endo-beta-N-acetylglucosaminidase H. In contrast, oligosaccharides present on the intracellular alpha-chain precursor were of the high mannose-type, remaining sensitive to endo-beta-N-acetylglucosaminidase H despite a long intracellular half-life of 2-3 h. The major [3H]mannose-labeled alpha-chain oligosaccharides identified after a 20-min pulse were Man8GlcNAc2 and Man9GlcNAc2. Following chase incubations, the major oligosaccharide accumulating intracellularly was Man6GlcNAc2, which was shown to contain a single alpha 1,2-linked mannose residue. Conversion of Man6GlcNAc2 to complex-type oligosaccharides occurred at the time of secretion since appreciable amounts of Man5GlcNAc2 or further processed structures could not be detected intracellularly. The subcellular locations of the alpha 1,2-mannosidase activities were studied using carbonyl cyanide m-chlorophenylhydrazone and monensin. Despite inhibiting the secretion of IgA, these inhibitors of protein migration did not effect the initial processing of Man9GlcNAc2 to Man6GlcNAc2. Furthermore, no large accumulation of Man5GlcNAc2 occurred, indicating the presence of two subcellular locations of alpha 1,2-mannosidase activity involved in oligosaccharide processing in MOPC 315 cells. Thus, the first three alpha 1,2-linked mannose residues were removed shortly after the alpha-chain was glycosylated, most likely in rough endoplasmic reticulum, since this processing occurred in the presence of carbonyl cyanide m-chlorophenylhydrazone. However, the removal of the final alpha 1,2-linked mannose residue as well as subsequent carbohydrate processing occurred just before IgA secretion, most likely in the trans Golgi complex since processing of Man6GlcNAc2 to Man5GlcNAc2 was greatly inhibited in the presence of monensin.

A novel 6:10 chromosomal translocation in the murine plasmacytoma NS-1.

Specific chromosomal abnormalities are regularly associated with many murine and human malignancies. In particular, the majority of murine plasmacytomas and human Burkitt's lymphomas contain a characteristic translocation which results in the juxtaposition of a cellular oncogene, c-myc, with the immunoglobulin heavy-chain gene locus, and this rearranged c-myc directs the synthesis of qualitatively and quantitatively abnormal transcripts which may have an aetiological role in the development of the transformed state in lymphoid malignancies. Similarly, rearrangement and abnormal expression of c-myb (ref. 10) and c-mos (ref. 11) has been reported in other murine lymphoid tumours. Here we describe a novel 6:10 chromosomal translocation in the murine plasmacytoma cell line NS-1 which juxtaposes the immunoglobulin Ck gene with a single-copy sequence of unknown function. The NS-1 plasmacytoma is a frequently used fusion partner in hybridoma production and is known to contain a rearranged c-myc gene and a genetic element which transforms normal mouse fibroblasts in DNA-mediated transfection assays. We conclude that individual B-cell tumours may contain multiple chromosomal translocations perhaps relevant to oncogenesis.

Immunohistochemical localization of choline acetyltransferase using a monoclonal antibody: A radioautographic method

Monoclonal antibodies to rat striatal choline acetyltransferase were produced by fusion of sensitized mouse lymphocytes with murine plasmacytoma (NS1) cells. Two stable anti-choline acetyltransferase lines were established by limiting dilution cloning. Specificity of antibody was established by the following criteria: (1) on an enzyme linked immunosorbant assay, antibodies reacted against choline acetyltransferase which was highly purified (2) by immunoprecipitation, monoclonal antibody bound to its antigen and precipitated choline acetyltransferase activity from solution, when used in conjunction with rabbit antimouse IgG (3) monoclonal antibody was shown to specifically localize cholinergic neurons. The monoclonal antibody to choline acetyltransferase was radiolabeled in culture by incubating hybridomas in medium containing 3H-labeled amino acids. This 3H-labeled antibody was used for radioautography on cryostat sections of rat peripheral and central nervous systems. In a sampling of areas, highly specific labeling of cholinergic structures was afforded at both light and electron microscopic levels. Double labeling of tyrosine hydroxylase, a catecholaminergic marker, and choline acetyltransferase was carried out by reacting sections first with the 3H-labeled antibody to choline acetyltransferase and then with rabbit antibody to tyrosine hydroxylase. The choline acetyltransferase label was radioautographically processed and tyrosine hydroxylase was visualized by the peroxidase-antiperoxidase method. The combined techniques of peroxidase and radioautographic histochemistry provide permanent electron dense labels which can be examined simultaneously within a single histologic section.

Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells.

The consistent appearance of specific chromosomal translocations in human Burkitt lymphomas and murine plasmacytomas has suggested that these translocations might play a role in malignant transformation. Here we show that transformation of these cells is frequently accompanied by the somatic rearrangement of a cellular analogue of an avian retrovirus transforming gene, c-myc. Moreover, we map c-myc to human chromosome 8 band q24, the chromosomal segment involved in the reciprocal Burkitt translocations [t(8;14), t(8;22) and t(2;8)]. In two t(8;14) human Burkitt cell lines, c-myc appears to have been translocated directly into a DNA restriction fragment that also encodes the immunoglobulin mu chain gene. In the case of a specific cloned fragment of DNA derived from a mouse plasmacytoma, we demonstrate directly that c-myc has been translocated into the immunoglobulin alpha switch region. Our data provide a molecular basis for considering the role that specific translocations might play in malignant transformation.

Effect of interferon on protein glycosylation and comparison with tunicamycin

The present wide interest in the mechanism of action of interferon (IFN) stems from its antiviral and anticancer potential. Possibly one of the more interesting insights into the antiviral action of IFN was recently described by Maheshwari et al.1. These authors, including one of us (K.O.), reported that IFN-treated cells release viral particles with low infectivity, and that this low infectivity seems to be related to the reduced amount of membrane protein glycosylation. The implications of this suggestion are exciting because inhibitors of glycosylation have antiviral properties, and also selectively kill transformed cells (see ref. 2 for review). An effect of IFN on the sysnthesis and cell-surface expression of glycoproteins could have an important role in its antiviral, anticancer and immunoregulatory actions. We have examined, for the first time, the effect of IFN on glycosylation of cellular proteins. We used murine fibroblasts (L-cells and NIH-3T3), plasmacytoma cells (P3 × 63 Ag8) and vesicular stomatitis virus (VSV) to compare the action of IFN with tunicamycin (TM), a known inhibitor of glycosylation2. Our results indicate that IFN does not inhibit the glycosylation of cellular or viral glycoproteins. Cells treated with IFN do not produce nonglycosylated species of glycoproteins nor the ‘glucose/glycosylation regulated proteins’3 (GRPs), in contrast to cells treated with tunicamycin4.

Multiple expression of Ig lambda-chain encoding RNA species in murine plasmacytoma cells.

The murine plasmacytoma MOPC 315, which synthesizes a complete IgA molecule containing lambda 2 light chains, is shown to synthesize a polypeptide related to the lambda 1 light chain. The abnormal lambda 1 polypeptide (m.w. approximately equal to 18,000) is encoded by a shorter polyA+ mRNA than the lambda 1 mRNAs of lambda 1-producing plasmacytomas. Polypeptides containing lambda 1-specific antigenic determinants have been found to be synthesized both in vitro by translations of RNA and in intact cells. HOPC-1, a lambda 1-producing plasmacytoma, was found to synthesize, in addition to the normal lambda 1-encoding mRNA, a lambda 2 RNA of normal length. A lambda 2-producing hybridoma does not appear to synthesize RNA encoding lambda 1 sequences. The results presented here show that more than 1 light chain gene may be transcribed within a single plasmacytoma cell. Although more than 1 light chain gene may be transcribed, the product of only 1 gene appears to be utilized for the synthesis of complete immunoglobulin molecules. This suggests novel mechanisms for the control of immunoglobulin expression.

Monoclonal rat antibodies to murine IgM determinants

A series of 6 hybrid clones are described which produced antibodies directed to murine IgM. These were derived by immunizing rats with W279 B-lymphoma cells and then fusing the immune spleen cells to enzyme-deficient murine plasmacytoma cell lines. Immunoenzymatic techniques were used to select clones producing desirable antibodies to cell surface or soluble antigens. Antibodies from 3 of the clones (293.14, 414.18 and 307.5) preferentially bound to idiotypic determinants of W279 immunoglobulin whereas the remaining 3 clones made antibodies which bound to various myeloma and normal cell surface IgM molecules. One IgM-specific clone (287.2) produced antibody of relatively low avidity. The two other clones (81.20 and 331.12) which secreted anti-μ antibodies appeared to be directed to determinants which differed in glutaraldehyde lability and expression in F(ab′) 2 preparations.

Use of monoclonal antibody to immunochemically characterize variant-specific surface coat glycoprotein from Trypanosoma rhodesiense.

Monoclonal antibodies were employed to study the molecular basis for charge heterogeneity in variant-specific surface coat glycoprotein prepared from clone CP3B4 of the Wellcome strain of Trypanosoma rhodesiense. Thirteen hybridomas secreting monoclonal antibodies specific for CP3B4 were obtained by fusing murine plasmacytoma cells to spleen cells from mice immunized with purified surface coat glycoprotein. The clone population of CP3B4 trypanosomes was shown to be homogeneous by means of immunofluorescent assays using culture supernatants from each of the 13 hybridomas. No cross-reactivity was found with other variant antigenic types of the same serodeme. Ascitic fluids were generated from 4 of the hybridomas and th molecular and epitopic specificities of the fluids or their IgG fractions were determined isoelectrofocusing of immunoprecipitates of radioiodinated glycoprotein antigen followed by autoradiography revealed that all 3 major components of the charge heterogeneous CP3B4 surface-coat glycoprotein were immunoprecipitated by each of the 4 monoclonal IgG fractions. Immunofluorescent staining of live trypanosomes was obtained with only one of the 4 ascitic fluids. The results show that charge heterogeneity does not derive from a heterogeneous population of parasites. Furthermore, the data indicate that there are at least 2 different epitopic specificities exhibited by the monoclonal antibodies tested and that each of the 3 charge heterogeneous components of the surface coat glycoprotein contains these epitopes. Charge heterogeneity of CP3B4 surface coat glycoprotein may be attributed to post-translational modification or to limited proteolysis.

Enhancement of Experimental Tumors in Mice by Treatment With Concanavalin A&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;

Weanling BALB/c mice given injections of 300 micrograms concanavalin A (Con A) prior to and at frequent intervals after challenge with Moloney murine sarcoma virus (M-MuSV), 3-methylcholanthrene (MCA), or TEPC-15 plasmacytoma cells showed an enhancement of tumor induction or development. With the M-MuSV and MCA systems, this enhancement was evidenced by larger tumors and, in the MCA system, by more devastating tumors. Regression of the M-MuSV-induced tumors was more prolonged in Con A-treated mice. With the TEPC-15 system, enhancement was evidenced by a more rapid mortality rate in treated animals.

Tumour immunoprophylaxis exerted by the antimicrococcus immunity II. Influence on the proliferation of murine plasmacytoma (MOPC 173) and Ehrlich carcinoma cells

The influence of the micrococcal vaccine on the proliferation of normal immunocompetent and neoplastic plasma (MOPC 173) and of carcinoma (Ehrlich ascites) cells is studied. BALB c mice and CDF 1 mice, hypervaccinated with Micrococcus Lysodeikticus, developed significantly ( 0.001 < P < 0.005) lower primary immune responses against sheep erythrocytes and also displayed impaired secondary immune responses. Administration of Bacillus Calmette-Guérin could partially restore the immunologic potential of vaccinated mice as measured by the capability of mice to answer with primary or secondary immune responses to sheep erythrocytes but did not increase immunoresponsiveness of normal mice sensitized at nearly optimal antigenic dose. Switching on a secondary antimicrococcus immune response after grafting 200,000 Ehrlich carcinoma cells in the peritoneum of BALB c mice resulted in a 30% increase in mean life span over control mice. However, mice hyperimmunized for months with Micrococcus lysodeikticus were offered the strongest immunoprotection and we found 67% of mice surviving to day 90 whereas the other vaccinated but tumour bearing animals showed a 29% increase in life span over control mice. Similarly, we demonstrated that 44% of BALB c mice, hyperimmunized for months, were able to reject a tumour challenge of 200,000 grafted MOPC 173 plasmacytoma cells, whereas the other micrococcus vaccinated but tumour bearing animals died with a 26% increase in mean survival time over control mice.